May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Persistency and Treatment Failure in Newly Diagnosed Open–angle Glaucoma Patients in the United Kingdom
Author Affiliations & Notes
  • Z. Zhou
    Outcomes Research, Pfizer Pharmaceutical Group, Peapack, NJ
  • R. Althin
    Outcomes Research, Pfizer Pharmaceutical Group, Sandwich, United Kingdom
  • B. Scassellati Sforzolini
    Outcomes Research, Pfizer Pharmaceutical Group, Sandwich, United Kingdom
  • Footnotes
    Commercial Relationships  Z. Zhou, Pfizer E; R. Althin, None; B. Scassellati Sforzolini, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4511. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Z. Zhou, R. Althin, B. Scassellati Sforzolini; Persistency and Treatment Failure in Newly Diagnosed Open–angle Glaucoma Patients in the United Kingdom . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4511.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To determine utilization patterns and calculate treatment failure and discontinuation rates in patients with open–angle glaucoma treated in the UK with any of 6 groups of IOP–lowering agents. Methods:The General Practice Research Database was used to identify newly diagnosed (after January 1, 1997) open–angle glaucoma patients who were naive to therapy with any of 6 index drug groups: carbonic anhydrase inhibitors, latanoprost, miotics, sympathomimetics, timolol, and other (non–timolol) beta–blockers. Analyses include drug treatment data for 1 year following diagnosis. Outcomes were: 1) time to therapy failure, defined as either change in index drug (replacement or addition of therapy) or patient referral for surgery, and 2) time to therapy discontinuation, defined as either therapy failure or no refill of the index drug in a period twice that covered by the first prescription fill. Cox proportional hazard regression and Kaplan–Meier and life–table methods were used to compare groups. Results:Among the 2,001 eligible patients, a beta–blocker other than timolol was the most widely prescribed (42.0%), followed by timolol (31.6%), carbonic anhydrase inhibitors (10.0%), and latanoprost (7.4%). Compared to latanoprost, those treated with any alternative agent were significantly more likely to fail (P≤0.005 for each comparison) and to discontinue (P≤0.05 for each comparison) therapy. Failure rates ranged from 13% (latanoprost) to 45% (sympathomimetics), and discontinuation rates ranged from 31% (latanoprost) to 63% (miotics). Conclusions:: Latanoprost–treated patients demonstrated lower rates of therapy failure and therapy discontinuation compared with patients treated with other widely used IOP–lowering medications, including beta–blockers.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×